Spotlight Medical’s myStage Dx AI breast cancer test has received CE marking under EU IVDR, enabling adoption in European oncology and pathology labs for recurrence risk assessment in ER+/HER2- early breast cancer patients.
The update integrates artificial intelligence into the system architecture to assist with case review, biomarker discovery, and laboratory operations.
Tempus has launched the ArteraAI Prostate Test, a CLIA-certified, CAP-accredited AI tool for metastatic hormone-sensitive prostate cancer, offering personalized risk estimates and designed to support treatment decisions, according to the company.
Synergen Health has introduced IGNITE, an AI-driven revenue cycle management platform for laboratories, aiming to streamline billing and reduce claim denials through automated processes and specialized RCM teams, according to the company.
Stellaris is designed to significantly improve how scientists are able to capture three-dimensional images of living cells and tissues.
Scopio Labs’ Full-Field Bone Marrow Aspirate Application has received EU IVDR certification, enabling high-throughput digital imaging at 100x resolution to support regulated hematology workflows on the X100 and X100HT platforms.